Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease

Abstract

Objective: A review of stereotactic body radiotherapy (SBRT) for oligometastases defined as three or fewer sites of isolated metastatic disease. The aim was to identify local control, overall survival (OS) and progression-free survival (PFS) of patients receiving SBRT for oligometastatic (OM) disease. Methods: Data were analysed for SBRT delivered between 01 September 2010 and 31 March 2014. End points included local control, PFS, OS and toxicity. Results: 76 patients received SBRT. The median age was 60 years (31-89 years). 44 were male. Median follow-up was 12.3 months (0.2-36.9 months). Major primary tumour sites included colorectal (38%), the breast (18%) and the prostate (12%). The treatment sites included lymph nodes (42%), the bone and spine (29%) and soft tissue (29%). 42% were previously treated with conventional radiotherapy. 45% were disease free after SBRT. 4% had local relapse, 45% had distant relapse, and 6% had local and distant relapse. Local control was 89%. The OS was 84.4% at 1 year and 63.2% at 2 years. PFS was 49.1% at 1 year and 26.2% at 2 years. Toxicities included duodenal ulcer and biliary stricture formation. Conclusion: SBRT can achieve durable control of OM lesions and results in minimal radiation-induced morbidity. Advances in knowledge: This cohort is one of the largest reported to date and contributes to the field of SBRT in oligometastases that is emerging as an important research area. It is the only study reported from the UK and uses a uniform technique throughout. The efficacy and low toxicity with durable control of local disease with this approach is shown, setting the foundations for future randomized studies.

Isolated splenic metastasis from a thymic carcinoma: A case report

“…Localized therapies including surgery and SBRT are radical treatment options to achieve control of metastatic sites. One recent study 21 of SBRT for oligometastases reported that local control rates was 84.4%, the overall survival (OS) was 84.4% at 1 y and 63.2% at 2 y. A partial response was observed in our case with local Cyberknife therapy and patient is still followed by our group closely.…”

Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy

“…treatment fractions. 35 The a-emitter radionuclide radium-223 has been shown to prolong survival compared with the best supportive care (14.9 vs 11.3 months; HR, 0.70; p 5 0.002) in patients with metastatic castrate-resistant CaP. 36 This systemic treatment is administered intravenously, accumulating at sites of bony metastatic disease and delivering highly damaging lowrange a particles to these sites.…”

Antioxidant and skin protection effect of morin upon UVA exposure

“…Antioxidants include glutathione (GSH), thioredoxin (Trx), and melatonin. Antioxidant enzymes include superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR), catalase (CAT), and heme oxygenase (HO) (Castro and Freeman 2001;Bhattacharya et al 2015). Among the major antioxidant mechanisms, Keap1-NRF2 is a major modulator of cytoprotective reactions against oxidation and stress and one of the core signaling proteins; it is a combination of NRF2 and Keap1, transcription factors that combine with antioxidant response element (ARE) along with small Maf protein.…”